Prev Arrow Stocks

West Pharmaceutical Services Inc. ($WST) Stock Forecast: Down 35.7% Today

Morpher AI identified a bearish signal. The stock price may continue to fall based on the momentum of the negative news.

What is West Pharmaceutical Services Inc.?

West Pharmaceutical Services, Inc. (NYSE: WST) is a global manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The company's stock had a bearish movement today.

Why is West Pharmaceutical Services Inc. going down?

WST stock is down 35.7% on Feb 13, 2025 20:35

  • Despite exceeding Q4 earnings expectations, West Pharmaceutical's stock experienced a decline attributed to weaker-than-anticipated guidance for 2025. This included adjusted EPS and revenue forecasts that missed consensus estimates.
  • The market responded negatively to the company's reduced earnings and revenue projections for the upcoming year, resulting in a notable sell-off of WST stock.
  • Investors reacted possibly due to disappointment stemming from the downward revision in West Pharmaceutical's future financial outlook. This sentiment drove the stock price lower during today's trading session.

WST Price Chart

WST Technical Analysis

WST News

West Pharmaceutical Stock Sinks On Weaker Than Expected 2025 Guidance - West Pharmaceutical Servs ( NYSE:WST )

West Pharmaceutical's Q4 adjusted EPS was $1.82, surpassing the $1.72 consensus, while revenue hit $748.8M, beating estimates of $740.47M. The company forecasts 2025 adjusted EPS of $6.00-$6.20, missing the $7.44 consensus, with revenue guidance of $2.875B-$2.91B below estimates

https://www.benzinga.com/general/health-care/25/02/43704837/west-pharmaceutical-stock-sinks-on-weaker-than-expected-2025-guidance

0 News Article Image West Pharmaceutical Stock Sinks On Weaker Than Expected 2025 Guidance - West Pharmaceutical Servs  ( NYSE:WST )

WST Stock Declines in Pre-Market Despite Q4 Earnings Beat, Margins Down

West Pharmaceutical's overall top line in the fourth quarter of 2024 continues to benefit from revenue growth in its Proprietary Products segment.

https://www.zacks.com/stock/news/2415585/wst-stock-declines-in-pre-market-despite-q4-earnings-beat-margins-down

1 Missing News Article Image WST Stock Declines in Pre-Market Despite Q4 Earnings Beat, Margins Down

West Pharmaceutical Services Inc. Price History

03.00.2025 - WST Stock was up 3.6%

  • Investors may have perceived WST's value favorably compared to its competitor Labcorp (LH).
  • The contrast between LH and WST could have positioned WST as an underestimated stock, appealing to more investors.
  • This positive perception of WST's value proposition likely contributed to the bullish performance of the stock today.

24.09.2024 - WST Stock was up 17.1%

  • West Pharmaceutical Services, Inc. (WST) reported adjusted EPS of $1.85, surpassing expectations and showing resilience in its financial performance.
  • Despite concerns about weakness in its Proprietary Products business and unfavorable currency movements, the company managed to exceed sales expectations, leading to the bullish movement in its stock.
  • Investors may be optimistic about the company's ability to navigate challenges and deliver strong results, driving the stock price higher.

24.09.2024 - WST Stock was up 19.6%

  • Despite the expected weakness in the Proprietary Products business, WST experienced a strong bullish movement.
  • The unfavorable currency movements might not have had as significant an impact on the stock as anticipated.
  • Investors may be optimistic about other aspects of WST's business or potential positive developments that are not captured.
  • The market may have reacted positively to other factors such as strong demand for healthcare products or overall market conditions.

13.01.2025 - WST Stock was down 32.6%

  • Despite a positive performance in West Pharmaceutical's Q4 earnings, the stock showed a drop in pre-market trading.
  • The decline in margins is considered a possible factor in the bearish movement, despite an increase in revenue in the Proprietary Products segment.
  • Investors seemed to place more emphasis on the margin decrease rather than the overall earnings beat, resulting in a pessimistic market outlook and the downward trend in the stock price.

12.05.2024 - WST Stock was up 5.4%

  • WST's stock showed a significant bullish movement today.
  • Short interest in WST has increased, indicating more investors are betting on a price decline.
  • Despite the rise in short interest, positive market sentiment and strong fundamentals seem to be driving WST's bullish movement, potentially overriding any selling pressure from short sellers.
  • Investors appear optimistic about WST's growth potential and market positioning, leading to a higher stock price despite the short interest.

25.03.2024 - WST Stock was down 5.1%

  • The company announced its recent financial results, potentially disappointing investors and causing a bearish market movement.
  • Concerns over adverse currency fluctuations impacting the business's financial performance in the first quarter of 2024 may have influenced the bearish trend.
  • Negative investor response to operational challenges within West Pharmaceutical Services could have fueled the significant bearish movement in the stock.

12.02.2024 - WST Stock was up 5.9%

  • The insider selling of shares by VP and Chief Accounting Officer Chad Winters might have initially raised concerns among investors.
  • However, the bullish movement in WST's stock could indicate that the selling activity was not perceived as a significant negative signal by the market.
  • Investors may have focused more on the overall positive outlook for the company and its industry, leading to increased buying interest and driving the stock price higher.
  • This suggests that despite the insider selling news, market participants remain optimistic about WST's future prospects.

13.02.2024 - WST Stock was up 5.9%

  • The surge in West Pharmaceutical's shares could be attributed to positive market sentiment and increased trading volume.
  • Despite an insider selling shares, the overall market response was positive, indicating that investors may be focusing more on the company's growth potential.
  • The earnings estimate revisions trend may have contributed to the bullish movement, suggesting that investors are optimistic about the company's future performance.
  • The insider selling shares might not have had a significant impact on the stock price, as the positive market sentiment overshadowed this development.

18.05.2024 - WST Stock was down 5.2%

  • Investors may be eyeing WST due to its recent underperformance in the market, leading to a bearish movement.
  • The key drivers of market outperformance and growth potential mentioned earlier may not have materialized as expected, causing a negative sentiment towards the stock.
  • Market participants might be reevaluating their positions in WST, leading to a sell-off in the stock as investors adjust their expectations based on the company's performance.

25.06.2024 - WST Stock was down 8.4%

  • Reported disappointing Q2 2024 earnings, with EPS of $1.52 missing estimates and revenue of $702.10 million falling short.
  • Attributed the decline in performance to a decrease in demand for its products across segments, coupled with elevated customer destocking.
  • The missed earnings and lowered outlook for 2024 could have led to a lack of investor confidence, resulting in a bearish movement in the stock price.
  • Concerns may arise about the company's ability to drive growth and profitability in the face of challenging market conditions, leading to a sell-off of WST shares.

25.06.2024 - WST Stock was down 12.1%

  • Today, West Pharmaceutical Services Inc. (WST) faced a substantial bearish movement in the stock market, potentially influenced by its Q2 earnings report:
  • The company revealed an EPS of $1.51, missing estimates, and revenue of $702.1 million falling short, indicating a weaker financial performance than expected.
  • The decline in Q2 profit and missed estimates likely contributed to investor concerns and the subsequent bearish market movement.
  • Additionally, the impact of unfavorable currency movements on the company's top and bottom lines might have further dampened investor sentiment, resulting in the downward trend in WST stock.

13.01.2025 - WST Stock was down 35.7%

  • Despite exceeding Q4 earnings expectations, West Pharmaceutical's stock experienced a decline attributed to weaker-than-anticipated guidance for 2025. This included adjusted EPS and revenue forecasts that missed consensus estimates.
  • The market responded negatively to the company's reduced earnings and revenue projections for the upcoming year, resulting in a notable sell-off of WST stock.
  • Investors reacted possibly due to disappointment stemming from the downward revision in West Pharmaceutical's future financial outlook. This sentiment drove the stock price lower during today's trading session.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.